Analysts expect that Mediwound Ltd (NASDAQ:MDWD) will post $800,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Mediwound’s earnings, with the lowest sales estimate coming in at $380,000.00 and the highest estimate coming in at $1.10 million. Mediwound posted sales of $530,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 50.9%. The business is scheduled to issue its next earnings report on Monday, March 18th.
On average, analysts expect that Mediwound will report full-year sales of $3.26 million for the current financial year, with estimates ranging from $2.79 million to $3.50 million. For the next financial year, analysts forecast that the company will report sales of $12.41 million, with estimates ranging from $5.81 million to $18.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Mediwound.
Mediwound (NASDAQ:MDWD) last announced its earnings results on Tuesday, November 13th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.08. The company had revenue of $0.86 million during the quarter, compared to the consensus estimate of $1.05 million. Mediwound had a negative net margin of 477.34% and a negative return on equity of 400.37%.
Several large investors have recently bought and sold shares of the company. Worth Venture Partners LLC acquired a new stake in shares of Mediwound during the third quarter worth $306,000. Nexthera Capital LP lifted its stake in shares of Mediwound by 288.3% during the third quarter. Nexthera Capital LP now owns 173,076 shares of the biopharmaceutical company’s stock worth $1,064,000 after buying an additional 128,500 shares during the period. Jefferies Group LLC acquired a new stake in shares of Mediwound during the third quarter worth $1,272,000. Renaissance Technologies LLC lifted its stake in shares of Mediwound by 37.4% during the third quarter. Renaissance Technologies LLC now owns 179,300 shares of the biopharmaceutical company’s stock worth $1,103,000 after buying an additional 48,800 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Mediwound by 1.3% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,126,058 shares of the biopharmaceutical company’s stock worth $13,075,000 after buying an additional 27,781 shares during the period. Institutional investors and hedge funds own 31.93% of the company’s stock.
MDWD traded down $0.05 during trading on Friday, hitting $4.35. The stock had a trading volume of 126,000 shares, compared to its average volume of 146,087. The company has a market cap of $117.12 million, a price-to-earnings ratio of -7.02 and a beta of 0.48. Mediwound has a twelve month low of $3.56 and a twelve month high of $7.35.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Featured Article: Treasury Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.